Last reviewed 2026-04-23 · How we verify

Changchun Werersai

Jiangsu Province Centers for Disease Control and Prevention · Phase 3 active Biologic

Changchun Werersai is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention. It is currently in Phase 3 development.

Changchun Werersai's mechanism of action is currently unknown.

Likelihood of approval

58.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Changchun Werersai
Sponsor	Jiangsu Province Centers for Disease Control and Prevention
Modality	Biologic
Phase	Phase 3

Mechanism of action

There is limited information available on the drug's mechanism of action, making it difficult to provide a detailed explanation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Changchun Werersai CI brief — competitive landscape report
Changchun Werersai updates RSS · CI watch RSS
Jiangsu Province Centers for Disease Control and Prevention portfolio CI

Frequently asked questions about Changchun Werersai

What is Changchun Werersai?

Changchun Werersai is a Biologic drug developed by Jiangsu Province Centers for Disease Control and Prevention.

How does Changchun Werersai work?

Changchun Werersai's mechanism of action is currently unknown.

Who makes Changchun Werersai?

Changchun Werersai is developed by Jiangsu Province Centers for Disease Control and Prevention (see full Jiangsu Province Centers for Disease Control and Prevention pipeline at /company/jiangsu-province-centers-for-disease-control-and-prevention).

What development phase is Changchun Werersai in?

Changchun Werersai is in Phase 3.

Manufacturer: Jiangsu Province Centers for Disease Control and Prevention — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing